Table 2.
Patient characteristics.
| Total (n = 9) | NYT (n = 4) | non-NYT (n = 5) | p-value | ||
|---|---|---|---|---|---|
| Age, yearsa | 60.0 (42–82) | 58.5 (42–82) | 60.0 (51–81) | 0.905 | |
| Sex | |||||
| Men | 4 (44) | 1 (25) | 3 (60) | 0.294 | |
| Women | 5 (56) | 3 (75) | 2 (40) | ||
| Body mass index, kg/㎡a | 27.6 (20.7–38.4) | 26.1 (20.7–38.4) | 27.6 (23.6–36.3) | 0.73 | |
| Time from symptom onset to admission, daysa | 8.5 (3–15) | 9.0 (8–11) | 1 | ||
| Comorbidities | |||||
| Diabetes | 4 (44) | 2 (50) | 2 (40) | 0.764 | |
| Hypertension | 3 (33) | 0(0) | 3 (60) | 0.058 | |
| Chronic kidney disease | 2 (22) | 2 (50) | 0 (0) | 0.073 | |
| Cerebrovascular diseases | 1 (11) | 0 (0) | 1 (20) | 0.343 | |
| Liver cirrhosis | 1 (11) | 1 (25) | 0 (0) | 0.236 | |
| Laboratory data | |||||
| WBC, /μLa | 5630 (4910–20,150) | 11,195 (4980–20,150) | 5630 (4910–10,330) | 0.73 | |
| RBC, ×104/μLa | 408 (320–496) | 396 (337–427) | 472 (320–496) | 0.413 | |
| PLT, ×104/μLa | 17.0 (5.8–26.7) | 19.9 (5.8–26.7) | 17.0 (11.4–22.5) | 0.73 | |
| Albumin, g/dLa | 2.80 (2.4–3.7) | 2.65 (2.4–2.8) | 2.90 (2.7–3.7) | 0.063 | |
| Prealbumin, mg/dLa | 8.6 (7.1–10.7) | 9.55 (7.1–10.7) | 7.90 (7.4–9.4) | 0.556 | |
| CRP, mg/dLa | 9.06 (1.06–15.84) | 8.91 (1.06–15.44) | 9.06 (2.93–15.84) | 0.905 | |
| KL6, U/mLa | 332 (124–932) | 392 (124–932) | 332 (186–719) | 1 | |
| PNI on admissiona | 30.7 (25.2–40.3) | 29.0 (25.2–32.5) | 31.2 (29.6–40.3) | 0.111 | |
| APACHE II scorea | 12.0 (8–16) | 11.5 (8–16) | 12.0 (10−13) | 1 | |
a
median (range),NYT: Ninjin'yoeito; PNI: Prognostic nutritional index; WBC: White blood cell; RBC: Red blood cell; PLT: platelet; CRP: C-reactive protein; APACHE II: Acute Physiology and Chronic Health Evaluation II.